FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES I	N BENEFICIAL	<b>OWNERSHIP</b>

Estimated average burden hours per response: Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL

OMB Number:

3235-0287

0.5

					01 36	Clion		IIVESUIIE	in Co	inparty Act	01 1	.540						
1. Name and Address of Reporting Person*  Hallal David			2. Issuer Name <b>and</b> Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN								Relationship of Reporting (Check all applicable)     X Director			,	Issuer Owner			
(Last)	(Fi	rst) (	Middle)										_		Officer elow)	(give title	Othe belo	er (specify w)
C/O ALEXION PHARMACEUTICALS, INC 352 KNOTTER DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 02/10/2015									Cl	hief Oper	ating Office	r			
(Street) CHESHI (City)			06410 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							ine) X F	,					
		Tabl	e I - No	n-Deriv	ative S	Secur	rities Acc	quired	, Dis	posed o	of, o	or Ben	efici	ally Ov	vned	d		
1. Title of Security (Instr. 3)  2. Transact Date (Month/Date)			Execution Date		ution Date,	Transaction Disposed Code (Instr.		ies Acquired (A) Of (D) (Instr. 3, 4			d 5) Se Be Ov	5. Amount of Securities Beneficially Dwned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership			
							Code	v	Amount (A)		(A) or (D)	Price	Trans		tion(s) and 4)		(Instr. 4)	
Common Stock, par value \$.0001 per share 02/10/2				/2015			S		1,980(1)	1,980 <sup>(1)</sup> D \$		\$171	1.15 124,033		4,033	D		
		Та					ies Acqu varrants,								ed			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, T ecurity or Exercise (Month/Day/Year) if any C		4. Transacti Code (Ins 8)	ion control of str.	5. Number of of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Expirati (Month/				8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)				

Date Exercisable

Expiration

Date

## **Explanation of Responses:**

1. This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.

## Remarks:

/s/ Michael Greco, Attorney-in-02/12/2015 Fact for David Hallal

\*\* Signature of Reporting Person Date

Amount Number

of Shares

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(A) (D)